Pharmacological studies with beclobrate, a new hypolipidemic agent

Area of Science:

• Pharmacology
• Medicinal Chemistry

Background:

• A novel diphenylmethane derivative, ethyl-(+/-)-2-[[alpha-(p-chlorophenyl)-p-tolyl]-oxy]-2-methylbutyrate (beclobrate), was investigated.
• Beclobrate exhibits potent hypolipidemic activity.

Purpose of the Study:

• To evaluate the hypolipidemic efficacy and safety profile of beclobrate in animal models.
• To compare the potency of beclobrate with clofibrate in reducing blood lipids.

Main Methods:

• Animal studies were conducted to assess hypocholesterolemic and hypotriglyceridemic effects.
• Dose-response relationships (ED25 values) were compared between beclobrate and clofibrate.
• Pharmacological tests were performed to evaluate peripheral and central effects.
• Interaction studies were conducted to assess potential risks in humans.

Main Results:

• Beclobrate is 11 times more potent than clofibrate in reducing cholesterol and 36 times more potent in reducing triglycerides in normally fed rats.
• Beclobrate is 20 times more effective than clofibrate in lowering fructose-induced hypertriglyceridemia.
• The hepatomegalic effect of beclobrate is 22 times that of clofibrate.
• High doses of beclobrate showed no significant peripheral or central effects, indicating high specificity for blood lipids.

Conclusions:

• Beclobrate exhibits significantly enhanced hypolipidemic activity compared to clofibrate.
• The drug demonstrates a high degree of specificity for blood lipid regulation.
• Pre-clinical studies suggest that beclobrate administration in humans should be largely free from risk.